Akeso (HKSE:09926) Accounts Payable : HK$388 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Accounts Payable?

Akeso's Accounts Payable for the quarter that ended in Dec. 2023 was HK$388 Mil.

Akeso's quarterly Accounts Payable declined from Dec. 2022 (HK$345 Mil) to Jun. 2023 (HK$296 Mil) but then increased from Jun. 2023 (HK$296 Mil) to Dec. 2023 (HK$388 Mil).

Akeso's annual Accounts Payable increased from Dec. 2021 (HK$253 Mil) to Dec. 2022 (HK$345 Mil) and increased from Dec. 2022 (HK$345 Mil) to Dec. 2023 (HK$388 Mil).

Akeso Accounts Payable Historical Data

The historical data trend for Akeso's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Accounts Payable Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

47.76

133.49

252.63

345.01

388.10

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable	Get a 7-Day Free Trial						252.63	326.26	345.01	295.66	388.10

Akeso Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Akeso Accounts Payable Related Terms

Thank you for viewing the detailed overview of Akeso's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso (HKSE:09926) Headlines

No Headlines